Understanding the origin and role of driver mutations in the case of Acute Myeloid Leukemia using a simulation study
DOI:
https://doi.org/10.47611/jsr.v12i4.2276Keywords:
Acute Myeloid Leukemia, Driver mutation, Birth-Death model, Tumor heterogeneityAbstract
Cancer is a leading cause of death worldwide, with millions of new cases diagnosed each year. Understanding how those cancers arise within individuals is a major challenge. Here we focus on Acute Myeloid Leukemia (AML) a type of blood cancer in the bone marrow that involves the formation of abnormal myeloid cells in an individual. Each year, 190,000 cases are diagnosed worldwide, of which 147,000 die. (Acute Myeloid Leukemia, n.d.)
In this paper, we aim to better understand the origin of AML and the role of driver mutations at the individual level.
We build a Birth-Death model to explore the role of mutation along with cell birth rate, cell death rate, and tissue size. Each simulation is individual-specific, which allows us to consider stochasticity across individuals.
We show that initial cell birth rate and cell death rate only play a minor role in cancer progression, even if there is a large inter-individual variance. On the contrary, we show that driver mutation rates play a more critical role in causing Acute Myeloid Leukemia. All in all, our paper highlights large variability in cancer progression across individuals and the major role of driver mutations in causing AML. This simulation model could be used to study other types of cancers.
Downloads
Metrics
References or Bibliography
(1) A, N. (2020, April). A unified simulation model for understanding the diversity of cancer evolution. BIOINFORMATICS AND GENOMICS, 8. 10.7717/peerj.8842
(2) Acute Myeloid Leukemia. (n.d.). AbbVie Science. Retrieved August 27, 2023, from https://www.abbviescience.com/tumor-types/acute-myeloid-leukemia.html
(3) Acute Myeloid Leukemia Treatment - NCI. (2022, August 19). National Cancer Institute. Retrieved August 25, 2023, from https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
(4) Cooper, G. M. (n.d.). The Development and Causes of Cancer. The Cell: A Molecular Approach. 2nd edition. https://www.ncbi.nlm.nih.gov/books/NBK9963/
(5) Hanahan, D. (2011). Hallmarks of Cancer: The Next Generation. 144(5). https://www.cell.com/fulltext/S0092-8674(11)00127-9
(6) Kaur, A. (2023, August). Origin of Acute Myeloid Leukemia. https://github.com/achi9/Origin-of-Acute-Myeloid-Leukemia
(7) Kimmel, M. (2013). Stochastic Hypothesis of Transition from Inborn Neutropenia to AML: Interactions of Cell Population Dynamics and Population Genetics. Front Oncol., 3(89). https://pubmed.ncbi.nlm.nih.gov/23641360/
(8) L., X. (2013). Cells of origin for cancer: an updated view from prostate cancer. Oncogene. 10.1038/onc.2012.541
(9) Link, D. C. (2019, January). MECHANISMS OF LEUKEMIC TRANSFORMATION IN CONGENITAL NEUTROPENIA. Current opinion in hematology. 10.1097/MOH.0000000000000479
(10) Seyfried, T. N. (2013). On the Origin of Cancer Metastasis. Critical reviews in oncogenesis, 18. 10.1615/critrevoncog.v18.i1-2.40
(11) Volz, E. M. (2013). Viral Phylodynamics. PLoS computational biology, 9(3), 12. 10.1371/journal.pcbi.1002947
(12) Zhu, X. (2021). Cancer evolution: A means by which tumors evade treatment. Biomedicine & Pharmacotherapy, 133(111016). doi.org/10.1016/j.biopha.2020.111016
Published
How to Cite
Issue
Section
Copyright (c) 2023 Achint Kaur, Noemie Lefrancq
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.